EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Insmed's Enterprise Value is $4,177.5 Mil.
Insmed's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-670.8 Mil. Therefore, Insmed's EV-to-EBIT for today is -6.23.
The historical rank and industry rank for Insmed's EV-to-EBIT or its related term are showing as below:
INSM'
s EV-to-EBIT Range Over the Past 10 Years
Min: -19.77 Med: -8.09 Max: -3.22
Current: -6.23
During the past 13 years, the highest EV-to-EBIT of Insmed was -3.22. The lowest was -19.77. And the median was -8.09.
INSM's EV-to-EBIT is ranked worse than 100% of 444
companies
in the Biotechnology industry
Industry Median: 8.185
vs INSM: -6.23
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Insmed's Enterprise Value for the quarter that ended in Dec. 2023 was $5,009.4 Mil.
Insmed's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-670.8 Mil. Insmed's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -13.39%.
Insmed EV-to-EBIT Historical Data
The historical data trend for Insmed's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Insmed's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insmed's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Insmed's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Insmed's EV-to-EBIT falls into.
Insmed's current Enterprise Value is $4,177.5 Mil.
Insmed's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-670.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insmed (NAS:INSM) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Insmed's Enterprise Value for the quarter that ended in Dec. 2023 was $5,009.4 Mil.
Insmed's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-670.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insmed EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Insmed's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INSM has been successfully added to your 